These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 12712410)

  • 1. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
    Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
    Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
    Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
    J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Yeh IT; Reddick RL; Kumar AP
    Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
    Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
    Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
    Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
    Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
    Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
    Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
    Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model.
    Bethel CR; Bieberich CJ
    Prostate; 2007 Dec; 67(16):1740-50. PubMed ID: 17929276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen-independent prostate cancer progression in the TRAMP model.
    Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
    Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
    Wang X; Colby JK; Yang P; Fischer SM; Newman RA; Klein RD
    Carcinogenesis; 2008 Jan; 29(1):120-8. PubMed ID: 17942462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
    Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
    Wikström P; Lindahl C; Bergh A
    Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.
    Caporali A; Davalli P; Astancolle S; D'Arca D; Brausi M; Bettuzzi S; Corti A
    Carcinogenesis; 2004 Nov; 25(11):2217-24. PubMed ID: 15358631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice.
    Yang D; Holt GE; Velders MP; Kwon ED; Kast WM
    Cancer Res; 2001 Aug; 61(15):5857-60. PubMed ID: 11479226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
    Tepaamorndech S; Huang L; Kirschke CP
    Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.
    Raghow S; Hooshdaran MZ; Katiyar S; Steiner MS
    Cancer Res; 2002 Mar; 62(5):1370-6. PubMed ID: 11888907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
    Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
    Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.